Literature DB >> 18451307

Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.

Ola Landgren1, Lynn R Goldin, Sigurdur Y Kristinsson, Elin A Helgadottir, Jan Samuelsson, Magnus Björkholm.   

Abstract

Previous small studies have reported familial clustering of myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF). We identified 6217 PV, 2838 ET, 1172 MF, and 812 MPN unclassifiable (NOS) patients diagnosed in Sweden, 43 550 controls, and first-degree relatives of cases (n = 24 577) and controls (n = 99 542). Using a marginal survival model, we calculated relative risks (RRs) and 95% confidence intervals as measures of familial aggregation. Relatives of MPN patients had significantly increased risks of PV (RR = 5.7; 3.5-9.1), ET (RR = 7.4; 3.7-14.8), and MPN NOS (RR = 7.5; 2.7-20.8). Analyses stratified by type of first-degree relative revealed consistently higher risks for siblings, compatible with a model of recessive genetic inheritance, which can be confirmed only by identifying the susceptibility gene(s). Mean age at MPN diagnosis was not different (P = .20) for affected relatives of cases (57.5 years) versus controls (60.6 years), and risk of MPN by age was not different for parents versus offspring of MPN cases (P = .10), providing no support for anticipation. Relatives of MPN patients had a borderline increased risk of chronic myeloid leukemia (CML; RR = 1.9; 0.9-3.8; P = .09). Our findings of 5- to 7-fold elevated risk of MPNs among first-degree relatives of MPN patients support the hypothesis that common, strong, shared susceptibility genes predispose to PV, ET, MF, and possibly CML.

Entities:  

Mesh:

Year:  2008        PMID: 18451307      PMCID: PMC2532797          DOI: 10.1182/blood-2008-03-143602

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

Review 1.  Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

Authors:  A Tefferi; J W Vardiman
Journal:  Leukemia       Date:  2007-09-20       Impact factor: 11.528

Review 2.  Oncogenes in myeloproliferative disorders.

Authors:  Ayalew Tefferi; D Gary Gilliland
Journal:  Cell Cycle       Date:  2007-03-24       Impact factor: 4.534

3.  Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

Authors:  Robert Kralovics; Soon-Siong Teo; Sai Li; Alexandre Theocharides; Andreas S Buser; Andre Tichelli; Radek C Skoda
Journal:  Blood       Date:  2006-05-04       Impact factor: 22.113

4.  Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation.

Authors:  Elisa Rumi; Francesco Passamonti; Matteo G Della Porta; Chiara Elena; Luca Arcaini; Laura Vanelli; Cecilia Del Curto; Daniela Pietra; Emanuela Boveri; Cristiana Pascutto; Mario Cazzola; Mario Lazzarino
Journal:  J Clin Oncol       Date:  2007-11-12       Impact factor: 44.544

5.  Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders.

Authors:  Christine Bellanné-Chantelot; Isabelle Chaumarel; Myriam Labopin; Florence Bellanger; Véronique Barbu; Claudia De Toma; François Delhommeau; Nicole Casadevall; William Vainchenker; Gilles Thomas; Albert Najman
Journal:  Blood       Date:  2006-03-14       Impact factor: 22.113

Review 6.  Biology and treatment of primary myelofibrosis.

Authors:  Ronald Hoffman; Damiano Rondelli
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2007

7.  Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders.

Authors:  Animesh Pardanani; Brooke L Fridley; Terra L Lasho; D Gary Gilliland; Ayalew Tefferi
Journal:  Blood       Date:  2007-11-15       Impact factor: 22.113

8.  20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis.

Authors:  Ayalew Tefferi; Naseema Gangat; Alexandra P Wolanskyj; Susan Schwager; Animesh Pardanani; Terra L Lasho; Ruben Mesa; Rebecca F McClure; Chin-Yang Li; Curtis A Hanson
Journal:  Eur J Haematol       Date:  2008-01-23       Impact factor: 2.997

9.  Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003.

Authors:  Ingemar Turesson; Martha S Linet; Magnus Björkholm; Sigurdur Y Kristinsson; Lynn R Goldin; Neil E Caporaso; Ola Landgren
Journal:  Int J Cancer       Date:  2007-11-15       Impact factor: 7.396

Review 10.  Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.

Authors:  Ayalew Tefferi; Michelle Elliott
Journal:  Semin Thromb Hemost       Date:  2007-06       Impact factor: 4.180

View more
  77 in total

1.  Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Lynn R Goldin; Sigurdur Y Kristinsson; Xueying Sharon Liang; Asa R Derolf; Ola Landgren; Magnus Björkholm
Journal:  J Clin Oncol       Date:  2011-12-12       Impact factor: 44.544

2.  A risk of essential thrombocythemia in carriers of constitutional CHEK2 gene mutations.

Authors:  Hanna Janiszewska; Aneta Bak; Maria Pilarska; Marta Heise; Anna Junkiert-Czarnecka; Małgorzata Kuliszkiewicz-Janus; Małgorzata Całbecka; Bozena Jaźwiec; Dariusz Wołowiec; Kazimierz Kuliczkowski; Olga Haus
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

Review 3.  JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?

Authors:  Linda M Scott; Vivienne I Rebel
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

4.  Germline RBBP6 mutations in familial myeloproliferative neoplasms.

Authors:  Ashot S Harutyunyan; Roberto Giambruno; Christian Krendl; Alexey Stukalov; Thorsten Klampfl; Tiina Berg; Doris Chen; Jelena D Milosevic Feenstra; Roland Jäger; Bettina Gisslinger; Heinz Gisslinger; Elisa Rumi; Francesco Passamonti; Daniela Pietra; André C Müller; Katja Parapatics; Florian P Breitwieser; Richard Herrmann; Jacques Colinge; Keiryn L Bennett; Giulio Superti-Furga; Mario Cazzola; Emma Hammond; Robert Kralovics
Journal:  Blood       Date:  2015-11-16       Impact factor: 22.113

Review 5.  Familial aggregation of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia with solid tumors and myeloid malignancies.

Authors:  Sigurdur Y Kristinsson; Lynn R Goldin; Ingemar Turesson; Magnus Björkholm; Ola Landgren
Journal:  Acta Haematol       Date:  2012-02-03       Impact factor: 2.195

6.  Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia.

Authors:  Lynn R Goldin; Magnus Björkholm; Sigurdur Y Kristinsson; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-03-13       Impact factor: 9.941

7.  Somatic and germline genetics at the JAK2 locus.

Authors:  Peter J Campbell
Journal:  Nat Genet       Date:  2009-04       Impact factor: 38.330

8.  Clinical utility gene card for: hereditary thrombocythemia.

Authors:  Kais Hussein; Melanie Percy; Mary Frances McMullin; Jiří Schwarz; Susanne Schnittger; Naomi Porret; Luz Maria Martinez-Aviles; Beatriz Bellosillo Paricio; Stéphane Giraudier; Radek Skoda; Eric Lippert; Sylvie Hermouet; Holger Cario
Journal:  Eur J Hum Genet       Date:  2013-06-05       Impact factor: 4.246

9.  No familial aggregation in chronic myeloid leukemia.

Authors:  Magnus Björkholm; Sigurdur Y Kristinsson; Ola Landgren; Lynn R Goldin
Journal:  Blood       Date:  2013-07-18       Impact factor: 22.113

10.  Autoimmunity and the risk of myeloproliferative neoplasms.

Authors:  Sigurdur Y Kristinsson; Ola Landgren; Jan Samuelsson; Magnus Björkholm; Lynn R Goldin
Journal:  Haematologica       Date:  2010-01-06       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.